Growing evidence suggests that exposure to natural environments may improve mood, attention, and selected cognitive functions, although the current literature remains insufficient to establish nature-based interventions as validated treatments for psychiatric disorders.

A systematic review of 12 studies found that vortioxetine consistently improved depressive symptoms in adults aged 65 years and older with major depressive disorder, but evidence for cognitive benefits remained mixed and largely confined to selected cognitive domains.

In a large multinational target-trial emulation, adults with serious mental illness who initiated GLP-1 receptor agonists experienced lower mortality and cardiovascular event rates than matched patients initiating SGLT2 inhibitors, though residual confounding remains a key limitation.

A single-day inhaled mebufotenin regimen produced rapid, sustained symptom reductions through day 8 in 10 patients with postpartum depression, but the uncontrolled trial provides an early clinical signal rather than comparative efficacy evidence.

Magnetoencephalography-based analysis of 263 patients with major depressive disorder identified five distinct brain connectivity profiles, each associated with differing symptom patterns, supporting the view that depression may encompass biologically heterogeneous subgroups rather than a single neurobiological condition.

In a French retrospective cohort, infants with Ewing sarcoma had favorable long-term survival after age-adjusted chemotherapy and predominantly surgical local control, although the 17-patient sample limits conclusions about treatment intensity and late toxicity.